# Signals Article: Putative Target Q00796 for Diabetic Kidney Disease
Background
Diabetic kidney disease (DKD) is a serious complication of diabetes, characterized by progressive kidney damage and a decline in renal function. It is a leading cause of end-stage renal disease worldwide. Despite advances in diabetes management, DKD remains a significant clinical challenge, and there is an urgent need for novel therapeutic targets to improve patient outcomes.
Data-mining rationale
In a recent reanalysis effort, UniProt entry Q00796 was identified as a putative target for DKD. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200316126, GDS:200178939, GDS:200218929, GDS:200156908, and GDS:200189005. Although Q00796 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing Q00796 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of Q00796's potential as a target for DKD. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of Q00796 as a target for DKD, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of DKD. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of Q00796. If validated, assessing the druggability of Q00796 via DGIdb and ChEMBL will be crucial for potential therapeutic development.